TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04787913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: herdimm
Description: In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: herdimm
Description: In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: herdimm
Description: In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: guardianmeasles
Description: A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: theotheredmundmeasles
Description: A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sbsnewsgeneric
Description: A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: publichealthagencycanadaflu
Description: A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: robertkochgeneric
Description: A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
Study: NCT04967924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular training
Description: Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports specific training
Description: Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
Study: NCT05815524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity training
Description: training on treadmill
Study: NCT06060691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaempferol
Description: Kaempferol
Study: NCT03985501

Intervention type: OTHER
Intervention: SCD newborn screening with the MS/MS method from Zentech
Description: The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
Study: NCT04303845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 140 mg of erenumab via subcutaneous injection
Study: NCT05261516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
Study: NCT04432610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol versus Nebivolol
Description: All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol versus Nebivolol
Description: All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period
Study: NCT05829083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asymmetric nasal cannula - DUET
Description: DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetric nasal cannula - DUET
Description: DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional nasal high flow cannula
Description: Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nasal high flow cannula
Description: Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions
Study: NCT06199700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: Intravenous infusion of Ketamine
Study: NCT06060691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kaempferol
Description: Kaempferol
Study: NCT06503276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm
Study: NCT05977660

Intervention type: DIAGNOSTIC_TEST
Intervention: Cumberland ankle instability tool for diagnose to determine ankle instability and its severity
Description: CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cumberland ankle instability tool for diagnose to determine ankle instability and its severity
Description: CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
Study: NCT06450327

Intervention type: OTHER
Intervention: This is a cross-sectional observational study
Description: There will be no intervention in the study.
Study: NCT05873777

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT
Description: Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
Study: NCT06450327

Intervention type: OTHER
Intervention: This is a cross-sectional observational study
Description: There will be no intervention in the study.

Intervention type: OTHER
Intervention: This is a cross-sectional observational study
Description: There will be no intervention in the study.

Intervention type: OTHER
Intervention: This is a cross-sectional observational study
Description: There will be no intervention in the study.
Study: NCT04903015

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: The following sequences of the MRI will be acquired during the inclusion visit:~* 3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~* multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~* continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~* resting-state fMRI: functional connectivity;~* 64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~* monovoxel spectroscopy of the mesencephalus with short echo time (TE).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: The following sequences of the MRI will be acquired during the inclusion visit:~* 3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~* multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~* continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~* resting-state fMRI: functional connectivity;~* 64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~* monovoxel spectroscopy of the mesencephalus with short echo time (TE).
Study: NCT06480799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre intervention
Description: Inulin fibre (5g) and Pectin fibre (15g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Maltodextrin (10g) served as a control/ placebo to compare the effects observed with inulin and pectin.
Study: NCT06035523

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoform™ Antibacterial
Description: Application of Endoform™ Antibacterial
Study: NCT06503276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-low dose radiotherapy
Description: 2 Gy radiotherapy will be administerd twice in the first cycle
Study: NCT05005832

Intervention type: OTHER
Intervention: multi day walking
Description: Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
Study: NCT05795725

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-assisted Fecal Microbiome Testing
Description: Next-generation sequencing of fecal samples and artificial intelligence analysis of test results

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy procedure
Study: NCT06257758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIO-01
Description: VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIO-01
Description: VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIO-01
Description: VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study.
Study: NCT05765955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: POLB 001
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: POLB 001
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: POLB 001
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05431309

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography
Description: Intervention strategies were selected according to CCTA results

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Treatment
Description: Traditional cardiovascular disease prevention strategy based on Chinese guideline
Study: NCT05619146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor-assisted arms and legs cycling
Description: The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
Study: NCT06035523

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoform™ Natural
Description: Application of Endoform™ Natural

Intervention type: DEVICE
Group type: OTHER
Intervention: Symphony™
Description: Application of Symphony™
Study: NCT05643469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-determination theory-based intervention plus instant messaging
Description: subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AWARD model
Description: Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
Study: NCT05506046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced nicotine message exposure
Description: Participants will be shown two messages about harms of reduced nicotine cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that reduced nicotine cigarettes will still have the rest of the harmful chemicals and cause diseases as the regular cigarettes, but they would make it easier to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified risk message exposure
Description: Participants will be shown two messages about electronic cigarettes as an alternative to regular cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that electronic cigarettes are less likely than regular cigarettes to cause severe diseases such as lung cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined message exposure (reduced nicotine + modified risk)
Description: Participants will be shown two messages, one from the reduced nicotine message set and one modified risk message set.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control message exposure
Description: Participants will be shown two messages about drinking bottled water. These will be selected from a pool of five message. The messages display specific water products and describe hydration as a healthy activity.
Study: NCT05047692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1
Description: Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1
Description: Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
Study: NCT05729360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GamCoviMab
Description: A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
Study: NCT05822076

Intervention type: PROCEDURE
Intervention: Paravertebral block (ropivacaine) left
Description: Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients

Intervention type: PROCEDURE
Intervention: Paravertebral block (ropivacaine) right
Description: Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
Study: NCT06178211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy: Adebrelimab
Description: Adebrelimab 1200mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: carboplatin plus nab-paclitaxel
Description: carboplatin plus nab-paclitaxel
Study: NCT04723927

Intervention type: OTHER
Intervention: Older adults
Description: The data for motor function and gait pattern analysis was obtained.
Study: NCT04839302

Intervention type: DRUG
Intervention: Indocyanine green solution
Description: Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
Study: NCT05188261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
Study: NCT05455203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT-ITT
Description: ADAPT-ITT is an implementation framework that guides adaptation of evidence-based interventions (EBI) for specific settings/populations. It will be used to adapt target interventions with a Family and Community Advisory Board. It has 8 phases: (1) Assess the risk profile of Black families in Paterson and East Orange, (2) Adopt or adapt an EBI, (3) Administer novel methods with families and children to facilitate the adaptation process, (4) Plan on what aspects of the EBI need to be adapted/how best to evaluate the adapted EBI, (5) Identify additional experts to assist in the adaptation process, (6) Integrate material from experts to adapt the EBI, (7) Train staff to implement the adapted intervention, and (8) Test the adapted intervention. Given time and financial constraints, five phases will be completed at the end of the pilot study. Qualitative data collected from individual dyad interviews will be used to inform the data.
Study: NCT06139783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise and dietary recommendations
Description: Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
Study: NCT06576947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants receive virtual reality treatment, 8 weeks of treatment/ 2 times a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation of the tibialis posterior nerve
Description: Participants receive neuromodulation of the tibialis posterior nerve8 weeks of treatment/ 2 times a week/ 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Participants receive pelvic floor muscle training 5 times a day for 9 weeks